Altamira Therapeutics Stock Buy Hold or Sell Recommendation
| CYTO Stock | USD 0.40 0.02 4.76% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Altamira Therapeutics is 'Strong Sell'. The recommendation algorithm takes into account all of Altamira Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Altamira Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide. In addition, we conduct extensive research on individual companies such as Altamira and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Altamira Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Altamira |
Execute Altamira Therapeutics Buy or Sell Advice
The Altamira recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Altamira Therapeutics. Macroaxis does not own or have any residual interests in Altamira Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Altamira Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Altamira Therapeutics Trading Alerts and Improvement Suggestions
| Altamira Therapeutics generated a negative expected return over the last 90 days | |
| Altamira Therapeutics has some characteristics of a very speculative penny stock | |
| Altamira Therapeutics has high historical volatility and very poor performance | |
| Altamira Therapeutics currently holds 99.66 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Altamira Therapeutics has a current ratio of 0.75, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Altamira Therapeutics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (3.87 M) with loss before overhead, payroll, taxes, and interest of (2.18 M). | |
| Altamira Therapeutics currently holds about 984.19 K in cash with (11.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Altamira Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: ARMISTICE CAPITAL, LLC Acquires New Stake in Altamira Therapeutics Ltd |
Altamira Therapeutics Returns Distribution Density
The distribution of Altamira Therapeutics' historical returns is an attempt to chart the uncertainty of Altamira Therapeutics' future price movements. The chart of the probability distribution of Altamira Therapeutics daily returns describes the distribution of returns around its average expected value. We use Altamira Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Altamira Therapeutics returns is essential to provide solid investment advice for Altamira Therapeutics.
| Mean Return | -1.13 | Value At Risk | -10.87 | Potential Upside | 6.98 | Standard Deviation | 4.70 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Altamira Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Altamira Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Altamira Therapeutics, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Altamira Therapeutics back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-09-30 | 101.4 K | Citadel Advisors Llc | 2024-09-30 | 14.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.9 K | Ubs Group Ag | 2024-06-30 | 1.7 K | Group One Trading, Lp | 2024-06-30 | 14.0 | Lri Investments, Llc | 2024-06-30 | 1.0 | Tower Research Capital Llc | 2024-06-30 | 0.0 |
Altamira Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (4.0M) | 9.9M | (10.3M) | (968.8K) | 602.0K | 632.1K | |
| Free Cash Flow | (11.4M) | (7.2M) | (17.0M) | (10.8M) | (11.5M) | (12.1M) | |
| Depreciation | 30.8K | 20.0K | 76.4K | 118.9K | 119.3K | 79.9K | |
| Other Non Cash Items | (601.1K) | 2.7M | 1.9M | 13.8M | (3.4M) | (3.2M) | |
| Capital Expenditures | 1.9M | 3.0M | 2.3M | 3.3M | 2.1M | 0.0 | |
| Net Income | (6.6M) | (8.2M) | (17.4M) | (26.5M) | (3.9M) | (4.1M) | |
| End Period Cash Flow | 1.4M | 11.3M | 984.2K | 15.4K | 617.4K | 586.5K | |
| Investments | (3.0M) | (2.3M) | (3.5M) | (2.1M) | 1.4M | 1.5M | |
| Net Borrowings | (9.3M) | (1.5M) | 1.5M | (68.7K) | (79.0K) | (83.0K) | |
| Change To Netincome | 664.6K | (568.3K) | 3.0M | 3.1M | 3.6M | 3.8M |
Altamira Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Altamira Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Altamira Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Altamira stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.15 | |
β | Beta against Dow Jones | 0.13 | |
σ | Overall volatility | 4.80 | |
Ir | Information ratio | -0.27 |
Altamira Therapeutics Volatility Alert
Altamira Therapeutics exhibits very low volatility with skewness of -0.32 and kurtosis of 0.71. Altamira Therapeutics is a potential penny stock. Although Altamira Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Altamira Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Altamira instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Altamira Therapeutics Fundamentals Vs Peers
Comparing Altamira Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Altamira Therapeutics' direct or indirect competition across all of the common fundamentals between Altamira Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Altamira Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Altamira Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Altamira Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Altamira Therapeutics to competition |
| Fundamentals | Altamira Therapeutics | Peer Average |
| Return On Equity | -3.69 | -0.31 |
| Return On Asset | -0.57 | -0.14 |
| Current Valuation | 1.88 M | 16.62 B |
| Shares Outstanding | 3.78 M | 571.82 M |
| Shares Owned By Insiders | 0.52 % | 10.09 % |
| Shares Owned By Institutions | 3.13 % | 39.21 % |
| Number Of Shares Shorted | 105.41 K | 4.71 M |
| Price To Book | 0.24 X | 9.51 X |
| Price To Sales | 0.64 X | 11.42 X |
| Gross Profit | (2.18 M) | 27.38 B |
| EBITDA | (1.35 M) | 3.9 B |
| Net Income | (3.87 M) | 570.98 M |
| Cash And Equivalents | 984.19 K | 2.7 B |
| Cash Per Share | 1.29 X | 5.01 X |
| Total Debt | 99.66 K | 5.32 B |
| Debt To Equity | 0.04 % | 48.70 % |
| Current Ratio | 0.77 X | 2.16 X |
| Book Value Per Share | 2.37 X | 1.93 K |
| Cash Flow From Operations | (11.51 M) | 971.22 M |
| Short Ratio | 1.08 X | 4.00 X |
| Earnings Per Share | 1.82 X | 3.12 X |
| Target Price | 4.5 | |
| Number Of Employees | 10 | 18.84 K |
| Beta | 2.44 | -0.15 |
| Market Capitalization | 1.52 M | 19.03 B |
| Total Asset | 7.69 M | 29.47 B |
| Retained Earnings | (18.05 M) | 9.33 B |
| Working Capital | 334.24 K | 1.48 B |
| Net Asset | 7.69 M |
Note: Acquisition by Lokay Kevin G of 10000 shares of Altamira Therapeutics at 11.5 subject to Rule 16b-3 [view details]
Altamira Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Altamira . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Altamira Therapeutics Buy or Sell Advice
When is the right time to buy or sell Altamira Therapeutics? Buying financial instruments such as Altamira Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Altamira Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Blockchain Thematic Idea Now
Blockchain
Companies across muliple sectors and different technology products and services that are engaged in some capacity with blockchain technolgoy or evolution of cryptocurrency. The Blockchain theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Blockchain Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Altamira Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.82 | Revenue Per Share 0.917 | Quarterly Revenue Growth (0.64) | Return On Assets (0.57) | Return On Equity (3.69) |
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.